Navigation Links
China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Date:2/19/2013

HONG KONG, Feb. 19, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the third quarter and first nine months of fiscal year 2013 on Tuesday, February 26, 2013, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Wednesday, February 27, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com.  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 90798569. 

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the third quarter fiscal 2013 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Tuesday, February 26, 2013 and in the Company's Report on Form 6-K for the month of February 2013 available on the Securities and Exchange Commission's website at www.sec.gov.  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company¡¦s website at http://www.chinacordbloodcorp.com.  

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
Email: robert.koepp@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
2. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
3. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
4. China Cord Blood Corporation to Further Consolidate its Corporate Structure
5. Biomaterials China News 1210 - Annual Subscription
6. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
7. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
9. China Biologic Products to Report Third Quarter 2012 Financial Results
10. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
11. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 The Global Implantable Biomaterials Market ... around 7.5% over the next decade to reach ... prominent trends that the market is witnessing include ... graft transplant surgeries and medical implants and technological ... categorized into immunomodulatory biomaterials, natural, polymers, hydrogels and ...
(Date:1/17/2017)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics company ... pathogens today announced the appointment of Mary Duseau as ... Company,s President and CEO since 2009, who will assume the position ... effective today. In addition, Ms. Duseau will join the ... ...
(Date:1/17/2017)... --  Pulmatrix, Inc . (NASDAQ: PULM ), ... to address serious pulmonary diseases, today announced that its ... of CF patients, PUR1900, has been designated as a ... & Drug Administration. Under the QIDP ... of novel drugs against important pathogens, Pulmatrix will receive ...
(Date:1/17/2017)... Research and Markets has announced the addition of ... and Companies" to their offering. ... The number of companies ... few years. More than 1,000 companies have been identified to ... are profiled in the report along with tabulation of 811 ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):